EMA Authorised: Hyftor (sirolimus) — Plusultra pharma GmbH

View source ↗

Summary

The EMA authorised Hyftor (sirolimus) by Plusultra pharma GmbH for angiofibroma and tuberous sclerosis complex with orphan medicine status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angiofibroma
• Tuberous Sclerosis Complex

Drugs mentioned

• Hyftor (sirolimus)

Snippet

Status: Authorised. Therapeutic area: Angiofibroma;Tuberous Sclerosis. MAH: Plusultra pharma GmbH. Decision date: 04/07/2025. Orphan medicine